<DOC>
	<DOCNO>NCT00129090</DOCNO>
	<brief_summary>According amendment 3 study address question intensification administration rituximab standard treatment patient newly diagnose aggressive B-Non Hodgkin Lymphoma ( B-NHL ) high risk ( aaIPI 2 3 ) result good time treatment failure ( TTTF )</brief_summary>
	<brief_title>Mega-CHOEP : Conventional Chemo Vs HD Chemo Followed Auto SCT Younger Pts With Aggressive Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>This study primarily design compare aggressive conventional chemotherapy repetitive high-dose ( HD ) therapy program use identical , effective drug high possible dose dose intensity with/without addition rituximab ( initially 4 treatment arm ) . In 2004 first amendment add order close two treatment arm without rituximab due recent data reveal significant advantage rituximab-treated patient CD20+lymphoma . A plan interim analysis 2010 reveal inferiority high-dose treatment thus 2nd amendment high-dose arm close additionally rituximab frequency raise 6 12 administration recent publication give hint advantage . The last amendment add 2010 adjust delay recruitment mainly due organisation problem . As high-dose arm close CD20+ B-lymphoma include past amendment 2 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1860 year age Risk group International Prognostic Index ( IPI ) 2 3 ( age adjust ) Performance status : Eastern Cooperative Oncology Group ( ECOG ) 03 Patient 's write informed consent Aggressive nonHodgkin 's lymphoma CD20+ histology Already initiate lymphoma therapy Serious accompany disorder impair organ function Bone marrow involvement &gt; 25 % Known hypersensibility medication use Known HIVpositivity Active hepatitis infection Suspicion patient compliance poor Simultaneous participation trial Prior chemo radiotherapy previous disorder Other concomitant tumour disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>